After years of work, European officials are nearing the finish line on the biggest shakeup to European pharmaceutical policy in decades, with major impacts on everything from how quickly new medicines are rolled out across the continent to how willing drugmakers are to invest in the E.U.
Looming in the background is the campaign from the U.S. to get Europe to pay more for medicines.
E.U. negotiators are in the process of reconciling three versions of the proposal put forth by different groups, and there’s some expectation that they could strike a deal on compromise legislation before the end of the year.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
